Vicarious Surgical (RBOT) Gains from Investment Securities (2021 - 2025)
Vicarious Surgical's (RBOT) quarterly Gains from Investment Securities came in at -$40000.0 in Q2 2025, up 97.48% year-on-year from -$20254.8 in Q2 2024, and down 143.01% on a QoQ basis from $93000.0 in Q1 2025.
Vicarious Surgical (RBOT) Gains from Investment Securities (2021 - 2025) Analysis & Trends
Vicarious Surgical (RBOT) has 5 years of Gains from Investment Securities data on file, last reported at -$40000.0 in Q2 2025.
- On a quarterly basis, Gains from Investment Securities rose 97.48% year-over-year to -$40000.0 in Q2 2025; TTM through Jun 2025 was -$267000.0, a 95.48% increase from a year earlier, with the FY2024 full-year figure at -$43000.0, up 99.17% from the prior year.
- Gains from Investment Securities for Q2 2025 stood at -$40000.0, down from $93000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for RBOT reached as high as $19.6 million in Q2 2021 and fell as low as -$17.6 million in Q2 2022.
- Historically, Gains from Investment Securities has averaged -$477433.3 across 5 years, with a median of -$40000.0 in 2025.
- Across the five-year window, Gains from Investment Securities sank 254.81% in 2023 and surged 102.93% in 2024, its largest moves.
- Year by year, Gains from Investment Securities stood at $19.6 million in 2021, then slumped by 144.51% to -$8.7 million in 2022, then soared by 82.94% to -$1.5 million in 2023, then jumped by 69.18% to -$458000.0 in 2024, then surged by 91.27% to -$40000.0 in 2025.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$40000.0 in Q2 2025, $93000.0 in Q1 2025, and -$458000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.64 Bn | 176.34 Bn | 6.27 Bn |
| 2 | Stryker | 129.04 Bn | 126.16 Bn | 3.81 Bn |
| 3 | Medtronic | 109.04 Bn | 99.82 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.54 Bn | 67.08 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.67 Bn | 45.00 Bn | 1.29 Bn |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.37 Bn | 26.08 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.92 Bn | 26.34 Bn | - |
| 9 | Koninklijke Philips | 25.48 Bn | 22.36 Bn | 2.07 Bn |
| 10 | Vicarious Surgical | 625,212.51 | -9.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -40,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | -458,000.00 |
| Dec 31, 2024 | -458,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | -1.49 Mn |
| Dec 31, 2023 | -1.49 Mn |
| Sep 30, 2023 | -4.70 Mn |
| Sep 30, 2023 | -4.70 Mn |
| Jun 30, 2023 | -5.08 Mn |
| Jun 30, 2023 | -5.08 Mn |
| Mar 31, 2023 | 6.08 Mn |
| Mar 31, 2023 | 6.08 Mn |